SCHEMBL6883200

SCHEMBL6883200

CCCCCCCOc1ccc(C=CC=C2SC(=S)N(CCC(=O)O)C2=O)cc1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AKR1B1 P15121 9/20 0.63
▸ MAPT P10636 8/20 0.62
▸ NCOA3 Q9Y6Q9 3/20 0.62
▸ MITF O75030 2/20 0.62
▸ RAB9A P51151 2/20 0.62
▸ PTPN1 P18031 3/20 0.61
▸ PTPN2 P17706 2/20 0.61
▸ ALDH1A1 P00352 2/20 0.56
▸ MEN1 O00255 4/20 0.55
▸ KMT2A Q03164 4/20 0.55
▸ NPC1 O15118 3/20 0.55
▸ FABP4 P15090 1/20 0.51
▸ POLB P06746 2/20 0.50
▸ TAS2R14 Q9NYV8 1/20 0.50
▸ USP2 O75604 1/20 0.50
▸ NSD2 O96028 1/20 0.50
▸ ALPL P05186 1/20 0.50
▸ GAA P10253 1/20 0.50
▸ APEX1 P27695 1/20 0.50
▸ MCL1 Q07820 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6887671 0.91 AKR1B1 (0.66) AKR1B1MAPTNCOA3MITFRAB9A
SCHEMBL6887580 0.90 AKR1B1 (0.67) AKR1B1MAPTNCOA3MITFRAB9A
SCHEMBL12008436 0.89 AKR1B1 (0.80) AKR1B1MAPTNCOA3MITFRAB9A
SCHEMBL6881279 0.89 AKR1B1 (0.80) AKR1B1MAPTNCOA3MITFRAB9A
SCHEMBL6887899 0.89 AKR1B1 (0.80) AKR1B1MAPTNCOA3MITFRAB9A
SCHEMBL6887897 0.89 AKR1B1 (0.80) AKR1B1MAPTNCOA3MITFRAB9A
SCHEMBL6885765 0.89 AKR1B1 (0.80) AKR1B1MAPTNCOA3MITFRAB9A
SCHEMBL6885769 0.89 AKR1B1 (0.80) AKR1B1MAPTNCOA3MITFRAB9A
SCHEMBL6881277 0.89 AKR1B1 (0.80) AKR1B1MAPTNCOA3MITFRAB9A
SCHEMBL6887875 0.86 AKR1B1 (0.56) AKR1B1MAPTNCOA3MITFRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6673816-B1 Rhodanine carboxylic acid derivatives for the treatment and prevention of metabolic bone disorders Esswein, Angelika (DE) 2004-01-06 — — US disclosed
US-20030032813-A1 Rhodanine carboxylic acid derivatives for the treatment and prevention of metabolic bone disorders ANGELIKA ESSWEIN, WOLFGANG SCHAEFER, AND KONRAD HONOLD 2003-02-13 — — US disclosed
EP-1117655-A1 RHODANINE CARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT AND PREVENTION OF METABOLIC BONE DISORDERS Esswein, Angelika (DE) 2001-07-25 — — EP disclosed
WO-2000018747-A1 RHODANINE CARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT AND PREVENTION OF METABOLIC BONE DISORDERS ROCHE DIAGNOSTICS GMBH (DE) 2000-04-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030032813-A1 Rhodanine carboxylic acid derivatives for the treatment and prevention of metabolic bone disorders NR1H4, NR1D1, NR1I2 AKR1B1 417/4885MAPT 3886/4885NCOA3 363/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback